PubMed Health⌕ Search

PubMed · 17072821

Smooth semiparametric receiver operating characteristic curves for continuous diagnostic tests.

Abstract

We propose a semiparametric kernel distribution function estimator, based on which a new smooth semiparametric estimator of the receiver operating characteristic (ROC) curve is constructed. We derive the asymptotic bias and variance of the newly proposed distribution function estimator and show that it is more efficient than the traditional non-parametric kernel distribution estimator. We also derive the asymptotic bias and variance of our new ROC curve estimator and show that it is more efficient than the smooth non-parametric ROC curve estimator proposed by Zou et al. (Stat. Med. 1997; 16:2143-2156) and Lloyd (J. Am. Stat. Assoc. 1998; 93:1356-1364). For our proposed estimators, we derive data-based methods for bandwidth selection. In addition, we present some results on the analysis of two real data sets. Finally, a simulation study is presented to show that our estimators are better than the non-parametric counterparts in terms of bias, standard error, and mean-square error.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Shuwen Wan, Biao Zhang. 2007-05-30. Smooth semiparametric receiver operating characteristic curves for continuous diagnostic tests.. https://doi.org/10.1002/sim.2726

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Redox potential measurement as a rapid method for microbiological testing and its validation for coliform determination.

The redox potential is one of the most complex indicators of the physiological state of microbial cultures and its measurement could be a useful tool for the qualitative and quantitative determination of the microbial contamination. During the bacterial growth, the redox potential of the medium decreases. The shape of the redox potential curve is characteristic on the type of microorganism, and the rate of the change (dE/dt) is proportional to the living cell concentration. Defining the time required to reach a significant change in redox potential as Time to Detection (TTD), similarly to the impedimetric measurements, a strict linear correlation could be established between the TTD and the logarithm of the initial concentration of microorganisms. On the base of this calibration curve, the determination of living cell concentration could be simplified. For the experiments, a computer-controlled multi-channel measuring system and software was developed by the authors. The redox potential measurement method was tested and validated for the determination of coliform bacteria. The results have proved the high efficiency and reliability of the new method.

Area Under Curve↗

Determination of N-methyl-4-isoleucine-cyclosporin (NIM811) in human whole blood by high performance liquid chromatography-tandem mass spectrometry.

A liquid chromatographic method with tandem mass spectrometric detection (LC-MS/MS) for the determination of N-methyl-4-isoleucine-cyclosporin (NIM811) was developed and validated over the concentration range 1-2500 ng/mL in human whole blood using a 0.05 mL sample volume. NIM811 and the internal standard, d(12)-cyclosporin A (d(12)-CsA), were extracted from blood using MTBE via liquid-liquid extraction. After evaporation of the organic solvent and reconstitution, a 10 microL aliquot of the resulting extract was injected onto the LC-MS/MS system. Chromatographic separation of NIM811 and internal standard was performed using a Waters Symmetry RP-8 (50 x 4.6 mm, 3 microm particle size) column. The mobile phase consists of 10 mm ammonium acetate in water (A) and acetonitrile (B), with 45% B from 0 to 0.2 min, 45 to 85% B from 0.2 to 0.8 min and 85% B from 0.8 to 2.2 min. The total run time was 3.5 min with a flow rate of 0.8 mL/min. The method was validated for sensitivity, linearity, reproducibility, stability, dilution integrity and recovery. The precision and accuracy of quality control samples at low (2.00 ng/mL), medium (20.0 and 400 ng/mL) and high (2000 ng/mL) concentrations were in the range 1.1-4.3% relative standard deviation (RSD) and -2.5-10.0% (bias), respectively, from three validation runs. The method has been used to measure the exposure of NIM811 in human subjects.

Area Under Curve↗

Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.

BACKGROUND AND OBJECTIVE: To assess the influence of hepatitis C virus (HCV) co-infection and the extent of liver fibrosis on lopinavir/ritonavir pharmacokinetics in HIV-infected patients without liver function impairment. METHODS: Cross-sectional, comparative study enrolling HIV-infected adults receiving lopinavir/ritonavir (400 mg/100 mg twice daily). HIV/HCV co-infected patients were grouped as having advanced fibrosis (HCV+/FIB+, n=7) or not (HCV+/FIB-, n=8) based on the FIB-4 index. A full concentration-time profile was obtained for each patient, and blood samples were collected before (0), and 1, 2, 4, 6, 8, 10 and 12 hours after a lopinavir/ritonavir dose. Lopinavir and ritonavir concentrations in plasma were determined by high-performance liquid chromatography. Maximum and minimum plasma concentrations (Cmax and Cmin), area under the plasma concentration-time curve from 0 to 12 hours (AUC12), apparent oral clearance at steady state (CLss/F), and apparent volume of distribution after oral administration (Vd/F) were calculated for each individual using a non-compartmental approach. RESULTS: Twenty-six HCV- and 22 HCV+patients were enrolled. Lopinavir and ritonavir pharmacokinetics were comparable between HCV- and HCV+patients. However, the Vd/F of lopinavir was 125% higher in HCV+/FIB+patients than in HCV-patients (p=0.015) and 107% higher than in HCV+/FIB-(p=0.040) patients. The CLss/F of ritonavir was 40% lower in HCV+/FIB+patients than in HCV-patients (p=0.005) and 44% lower than in HCV+/FIB-patients (p=0.040). Thus, for ritonavir AUC12, Cmax and Cmin in HCV+/FIB+patients were 63%, 86% and 100% higher, respectively, when compared with those parameters in HCV-patients (p=0.005, p=0.012 and p=0.015, respectively), and 80%, 86% and 100% higher, respectively, when compared with levels in HCV+/FIB- patients (p=0.040, p=0.040 and p=0.029, respectively). CONCLUSION: Lopinavir exposure is similar in HIV-infected patients with or without HCV co-infection and without liver function impairment. However, ritonavir exposure may be higher in this setting, particularly in individuals with advanced liver fibrosis.

Area Under Curve↗